Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans.

Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, Sigal N, Feng Y, Bristow L, Tak-Yin Tsang O, Wagh D, Coller J, Pellegrini KL, Kazmin D, Alaaeddine G, Leung WS, Chan JMC, Chik TSH, Choi CYC, Huerta C, Paine McCullough M, Lv H, Anderson E, Edupuganti S, Upadhyay AA, Bosinger SE, Maecker HT, Khatri P, Rouphael N, Peiris M, Pulendran B. · 2020

Read Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. by Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, Sigal N, Feng Y, Bristow L, Tak-Yin Tsang O, Wagh D, Coller J, Pellegrini KL, Kazmin D, Alaaeddine G, Leung WS, Chan JMC, Chik TSH, Choi CYC, Huerta C, Paine McCullough M, Lv H, Anderson E, Edupuganti S, Upadhyay AA, Bosinger SE, Maecker HT, Khatri P, Rouphael N, Peiris M, Pulendran B. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7665312.txt.

Introduction

Arunachalam and co-authors apply systems biology to immunity in COVID-19. They profiled patients whose illness ranged from mild to severe. The aim was to learn how the immune response shapes how sick a person gets. That link was still unclear when the work was done.

The team combined many immune measures for each patient rather than testing one marker at a time. Their profiles set mild and severe disease apart. Alongside a companion atlas study, the work gives a map of immune change in COVID-19. The authors offer it as a guide for picking treatments that target the immune response.

Catalog record

CREATORArunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, Sigal N, Feng Y, Bristow L, Tak-Yin Tsang O, Wagh D, Coller J, Pellegrini KL, Kazmin D, Alaaeddine G, Leung WS, Chan JMC, Chik TSH, Choi CYC, Huerta C, Paine McCullough M, Lv H, Anderson E, Edupuganti S, Upadhyay AA, Bosinger SE, Maecker HT, Khatri P, Rouphael N, Peiris M, Pulendran B.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7665312

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans By Prabhu S Arunachalam, Florian Wimmers, Chris Ka Pun Mok, Ranawaka A P M Perera, Madeleine Scott, Thomas Hagan, Natalia Sigal, Yupeng Feng, Laurel Bristow, Owen Tak-Yin Tsang, Dhananjay Wagh, John Coller Published in: Science (New York, N.y.) DOI: 10.1126/science.abc6261 ABSTRACT Immune profiling of COVID-19 patients Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathew et al. present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalam et al. report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions. Science, this issue p. eabc8511, p. 1210 The recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, in December 2019 and its rapid international spread caused a global pandemic. Research has moved rapidly in isolating, sequencing, and cloning the virus; developing diagnostic kits; and testing candidate vaccines. However, key questions remain about the dynamic interaction between the human immune system and the SARS-CoV-2 virus. Coronavirus disease 2019 (COVID-19) presents with a spectrum of clinical phenotypes, with most patients exhibiting mild to moderate symptoms and 15% of patients progressing, typically within a week, to severe or critical disease that requires hospitalization (1). A minority of those who are hospitalized develop acute respiratory disease syndrome (ARDS) and require mechanical ventilation. Epidemiological data so far suggest that COVID-19 has a case fatality rate several times greater than that of seasonal influenza (1). The elderly and individuals with underlying medical comorbidities such as cardiovascular disease, diabetes mellitus, chronic lung disease, chronic kidney disease, obesity, hypertension, or cancer have a much higher mortality rate than healthy young adults (2). The underlying causes of this difference are unknown, but they may be due to an impaired interferon (IFN) response and dysregulated inflammatory responses, as have been observed with other zoonotic coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (3). Current research is uncovering how the adaptive immune response to SARS-CoV-2 is induced with optimal functional capacities to clear SARS-CoV-2 viral infection (4–6). Understanding the immunological mechanisms underlying the diverse clinical presentations of COVID-19 is a crucial step in the design of rational therapeutic strategies. Recent studies have suggested that COVID-19 patients are characterized by lymphopenia and increased numbers of neutrophils (7–9). Most patients with severe COVID-19 exhibit enhanced levels of proinflammatory cytokines including interleukin-6 (IL-6) and IL-1β as well as MCP-1, IP-10, and granulocyte colony-stimulating factor (G-CSF) in the plasma (10). It has been proposed that high levels of proinflammatory cytokines might lead to shock as well as respiratory failure or multiple organ failure, and several trials to assess inflammatory mediators are under way (11). However, little is known about the immunological mechanisms underlying COVID-19 severity and the extent to which they differ from the immune responses to other respiratory viruses. Furthermore, the question of whether individuals in different parts of the world respond differently to SARS-CoV-2 remains unknown. In this study, we used a systems biological approach [mass cytometry and single-cell transcriptomics of leukocytes, transcriptomics of bulk peripheral blood mononuclear cells (PBMCs), and multiplex analysis of cytokines in plasma] to analyze the immune response in 76 COVID-19 patients and 69 age- and sex-matched controls from two geographically distant cohorts. ANALYSIS OF PERIPHERAL BLOOD LEUKOCYTES FROM COVID-19 PATIENTS BY MASS CYTOMETRY COVID-19–infected patient samples and samples from age- and sex-matched healthy controls were obtained from two independent cohorts: (i) the Princess Margaret Hospital at Hong Kong University and (ii) the Hope Clinic at Emory University in Atlanta, Georgia, United States. Patient characteristics and the different assays performed are shown in Table 1. We used mass cytometry to assess immune responses to SARS-CoV-2 infection in 52 COVID-19 patients, who were confirmed positive for viral RNA by polymerase chain reaction (PCR), and 62 age- and gender-matched healthy controls distributed between the two cohorts. To characterize immune cell phenotypes in PBMCs, we used a phospho-CyTOF panel that includes 22 cell surface markers and 12 intracellular markers against an assortment of kinases and phospho-specific epitopes of signaling molecules and H3K27ac—a marker of histone modification that drives epigenetic remodeling (12, 13) (table S1). The experimental strategy is described in Fig. 1A. The phospho-CyTOF identified 12 main subtypes of innate and adaptive immune cells in both cohorts, as represented in the t-distributed stochastic neighbor embedding (t-SNE) plots (Fig. 1B). There was a notable increase in the frequency of plasmablast and effector CD8 T cells in all infected individuals (Fig. 1B) in both cohorts, as has been described recently in other studies (6, 8, 14). Of note, the kinetics of the CD8 effector T cell response were prolonged and continued to increase up to day 40 after onset of the symptoms (fig. S1). [Table: Patient characteristics and number of samples used in different assays.NA, not applicable.] [Figure: Mass cytometry analysis of human peripheral blood leukocytes from COVID-19 patients.(A) A schematic representation of the experimental strategy. PFA, paraformaldehyde. (B) Representation of mass cytometry–identified cell clusters visualized by t-SNE in two-dimensional space. The box plots on the bottom show frequency of plasmablasts (CD3−, CD20−, CD56−, HLA-DR+, CD14−, CD16−, CD11c−, CD123−, CD19lo, CD27hi, and CD38hi) and effector CD8 T cells (CD3+, CD8+, CD38hi, and HLA-DRhi) in both cohorts. (C) Frequencies of pDCs (CD3−, CD20−, CD56−, HLA-DR+, CD14−, CD16−, CD11c−, and CD123+) in healthy and COVID-19–infected individuals in both cohorts. (D and E) Box plots showing fold change (FC) of pS6 staining in pDCs (D) and IκBα staining in mDCs (E) relative to the medians of healthy controls. The histograms on the right depict representative staining of the same. (F) Distinguishing features [false discovery rate (FDR) < 0.01] through linear modeling analysis of the mass cytometry data between healthy and infected subjects. In all box plots, the boxes show median, upper, and lower quartiles. The whiskers show 5th to 95th percentiles. Each dot represents an individual sample (healthy: n = 17 and 45; infected: n = 19 and 54, for Atlanta and Hong Kong cohorts, respectively). For the t-SNE analysis, n = 34 and 60 for Atlanta and Hong Kong cohorts, respectively. The colors of the dots indicate the severity of clinical disease, as shown in the legends. The differences between the groups were measured by Mann-Whitney rank sum test (Wilcoxon, paired = FALSE). The P values depicting significance are shown within the box plots.] We next used manual gating to identify 25 immune cell subsets (fig. S2) and determined whether there were changes in the frequency or signaling molecules of innate immune cell populations consistent between the two cohorts. There were several differences, but notably the frequency of plasmacytoid dendritic cells (pDCs) was significantly reduced in the PBMCs of SARS-CoV-2–infected individuals in both cohorts (Fig. 1C). The kinetics of pDC response did not show an association with the time since symptom onset (fig. S1C). Neither did the observed changes

Read the complete text